The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Open accessAbstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers. Neoadjuvant combination treatment with nivolumab and ipilimumab in patients with high-risk melanoma results in higher response rates than nivolumab monotherapy and warrants future optimization of dosing regimens to preserve efficacy while limiting toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“analyses of samples derived from patients with melanoma who received neoadjuvant ICIs112,113 have revealed the presence of the three primary patterns of T cell infiltration identified in solid tumours.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [113]
Experimental — accuracy not yet measuredIn the citing paper
“Studies in melanoma using higher dosages of ipilimumab reported enhanced immune infiltration in responding tumors17.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Amaria and colleagues17 demonstrated that a more clonal T-cell repertoire at baseline correlated with response to neoadjuvant ICI therapy in patients with melanoma, with further expansion of the pre-existing high-frequency clones with treatment.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [17]
In the citing paper
“Key roles of TGF-β1 in suppressing the adaptive immune system are apparent from the lymphoproliferative autoimmune phenotype of Tgfb1−/− mice197–199, and similar phenotypes following selective ablation of TGF-β signaling components within CD4+ and CD8+ T cells200.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [198]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,508
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,055
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Research works printed but not linked: 1
- Edge, S. B. AJCC Cancer Staging Manual 7th edn (Springer, New York, 2010).
Cited by
Sorted by citations
Items 501–600 of 838
Cina, M. L., Venegas, J., & Young, A. (2023) · Immunological Reviews · doi:10.1111/imr.13250 · Cited by 10
Block, M. S., Nelson, G. D., Chen, J., Johnson, S. P., Yang, L., Flotte, T. J., Grewal, E. P., McWilliams, R. R., Kottschade, L. A., Domingo‐Musibay, E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011706 · Cited by 10
Dong, X., Pan, P., Zhang, Q., Ye, J., Bao, P., Zeng, X., & Zhang, X. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101555 · Cited by 9
Is single versus combination therapy problematic in the treatment of cutaneous melanoma?
Krattinger, R., Ramelyte, E., Dornbierer, J., & Dummer, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1650641 · Cited by 9
Neo-Adjuvant Therapy for Metastatic Melanoma
Kuijpers, A. M. J., & van Akkooi, A. C. J. (2024) · Cancers · doi:10.3390/cancers16071247 · Cited by 8
Risk of Lymph Node Metastasis in T2 Colon Cancer: A Nationwide Population-Based Cohort Study
Hanevelt, J., Brohet, R. M., Moons, L. M. G., Laclé, M. M., Vleggaar, F. P., van Westreenen, H. L., & Cappel, W. H. D. V. T. N. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-16921-w · Cited by 8
Microsystem technologies for accelerating the discovery and translation of immunotherapies
Wang, Z., Liu, C. Y., Chen, K., Song, J. W., & Kelley, S. O. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01268-4 · Cited by 8
Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
Xu, J., Wu, Y., Xu, Y., Qiu, Y., Li, X., Song, Y., & Zhang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802672 · Cited by 8
Huang, P., Xu, L., Li, L., Ke, Y., Zhang, M., Zhang, M., Lu, K., Jin, M., & Huang, G. (2022) · Genes · doi:10.3390/genes13060951 · Cited by 8
Vathiotis, I. A., Johnson, J. M., Luginbuhl, A., Cognetti, D. M., Curry, J., & Argiris, A. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102437 · Cited by 8
Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
Hannani, D., Leplus, E., Laulagnier, K., Chaperot, L., & Plumas, J. (2023) · Genes & Cancer · doi:10.18632/genesandcancer.229 · Cited by 8
Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
Hirshoren, N., Yoeli‐Bik, R., Cohen, J. E., Weinberger, J. M., Kaplan, N., Merims, S., Peretz, T., & Lotem, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231038 · Cited by 8
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma
Spagnolo, F., Croce, E., Boutros, A., Tanda, E. T., Cecchi, F., Mascherini, M., Solari, N., Cafiero, F., & Queirolo, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760847 · Cited by 7
Adjuvant Nodal Radiation Therapy for Melanoma in the Era of Immunotherapy
Mitra, D., Bishop, A. J., & Guadagnolo, B. A. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.006 · Cited by 8
Chubenko, V. A., Inusilaev, G., Имянитов, Е. Н., & Moiseyenko, V. M. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-236144 · Cited by 8
Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
Salama, A. K. S., Palta, M., Rushing, C. N., Selim, M. A., Linney, K. N., Czito, B. G., Yoo, D. S., Hanks, B. A., Beasley, G. M., Mosca, P. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2452 · Cited by 8
Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety
Nebhan, C. A., & Johnson, D. B. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1882856 · Cited by 8
Whooley, J., Alazzawi, M., Donlon, N. E., Bolger, J. C., & Robb, W. B. (2021) · Diseases of the Esophagus · doi:10.1093/dote/doab063 · Cited by 8
Ba, H., Zhu, F., Zhang, X., Mei, Z., & Zhu, Y. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148918 · Cited by 8
Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma
Ma, V. T.-L., Haring, C. T., Warrier, G., & Swiecicki, P. L. (2020) · Facial Plastic Surgery · doi:10.1055/s-0040-1709126 · Cited by 9
Zhou, S., Horita, N., Shao, T. H., Harrington, M. D., & Fujiwara, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241257874 · Cited by 8
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches
Amin, T., Hossain, A., Jerin, N., Mahmud, I., Rahman, M. A., Islam, S. M. R., & Islam, S. M. B. U. (2024) · Cancer Control · doi:10.1177/10732748241290067 · Cited by 7
Cuiffo, B., Maxwell, M., Yan, D., Guemiri, R., Boone, A., Bellet, D., Rivest, B., Cardia, J. P., Robert, C., & Fricker, S. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501679 · Cited by 8
Jayathilaka, B., Mian, F., Cockwill, J., Franchini, F., Au‐Yeung, G., & IJzerman, M. J. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104601 · Cited by 7
Facts and Hopes: Toward the Next Quantum Leap in Melanoma
Flaherty, K. T., Aplin, A. E., Davies, M. A., Hacohen, N., Herlyn, M., Hoon, D. S. �., Hwu, P., Lotem, M., Mulé, J. J., Wargo, J. A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0278 · Cited by 8
Self-citationWithin and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression
Puviindran, B. J., Wallace, S., Ayasoufi, K., Lerner, E., & Fecci, P. E. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf006 · Cited by 9
Rawson, R. V., Maher, N. G., Menzies, A. M., Lo, S., Ardakani, N. M., Jackett, L. A., Vergara, I. A., Pennington, T. E., Shannon, K. F., Ch’ng, S., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1237 · Cited by 8
Self-citationHooiveld-Noeken, J. S., Eggen, A. C., Rácz, E., de Vries, E. G. E., Reyners, A. K. L., & Jalving, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103855 · Cited by 7
Neoadjuvant Therapy in Melanoma: Where Are We Now?
Saad, M., & Tarhini, A. A. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01369-6 · Cited by 7
Kidman, J., Zemek, R. M., Sidhom, J.-W., Corrêa, D., Principe, N., Sheikh, F., Fear, V. S., Forbes, C. A., Chopra, A., Boon, L., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2345859 · Cited by 7
Neoadjuvant therapy for melanoma: past, present, and future
Therien, A. D., Chime-Eze, C. M., Rhodin, K. E., & Beasley, G. M. (2024) · Surgical Oncology · doi:10.1016/j.suronc.2024.102127 · Cited by 8
Sam, I., Benhamouda, N., Biard, L., Meda, L. D., Desseaux, K., Baroudjan, B., Nakouri, I., Renaud, M., Sadoux, A., Alkatrib, M., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00203-9 · Cited by 7
Immune Checkpoint Therapies for Melanoma
Buchbinder, E. I. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.013 · Cited by 7
Jia, W., Lu, X., Liu, Q., Li, L., Liu, S., Liu, F., Fu, Y. S., Fan, X., Yang, Y., Qi, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.554040 · Cited by 7
Werner, F., Wagner, C., Simon, M., Glatz, K., Mertz, K. D., Laubli, H. P., Richtig, E., Griss, J., & Wagner, S. N. (2021) · Diagnostics · doi:10.3390/diagnostics11071238 · Cited by 8
Educational Review: Neoadjuvant Approaches to Melanoma
Sharon, C. E., & Karakousis, G. C. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12224-6 · Cited by 7
Chen, F., Qiu, L., Mu, Y., Sun, S., Yuan, Y., Shang, P., Ji, B., & Wang, Q. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.893372 · Cited by 7
Mooradian, M. J., & Sullivan, R. J. (2023) · Cancer · doi:10.1002/cncr.34806 · Cited by 9
Li, K., He, M., Wan, S., Chen, S., Wang, C., Li, X., & Yang, L. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000591 · Cited by 7
CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder Cancer
Semeniuk-Wojtaś, A., Modzelewska, M., Poddębniak-Strama, K., Kołaczyńska, S., Lubas, A., Górnicka, B., Jakieła, A., & Stec, R. (2023) · Cancers · doi:10.3390/cancers15235529 · Cited by 12
Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment
Rutkowski, P. L., & Mandalà, M. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.107969 · Cited by 8
Spillane, A. J., Menzies, A. M., & van Akkooi, A. C. J. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08566-8 · Cited by 7
Immunotherapy and Potential Predictive Biomarkers in the Treatment of Neuroendocrine Neoplasia
Xu, G., Wang, Y., Zhang, H., She, X., & Yang, J. (2020) · Future Oncology · doi:10.2217/fon-2020-0703 · Cited by 7
Karapetyan, L., & Kirkwood, J. M. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.003 · Cited by 7
neoepiscope improves neoepitope prediction with multi-variant phasingPreprint
Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/418129 · Cited by 7
Intratumoral immunotherapy prior to cancer surgery, a promising therapeutic approach
Silihe, K. K., & Fiering, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545000 · Cited by 6
Versluis, J. M., Shehwana, H., Elens, R., Menzies, A. M., Reijers, I. L. M., Dimitriadis, P., Maher, N. G., van der Veldt, A. A. M., Kapiteijn, E., Broeks, A., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01118-9 · Cited by 6
Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.004 · Cited by 9
Kendra, K. L., Bellasea, S. L., Eroglu, Z., Hu‐Lieskovan, S., Campbell, K. M., Carson, W. E., Wada, D. A., Plaza, J. A., In, G. K., Ikeguchi, A. P., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01113-y · Cited by 7
Self-citation“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
Garutti, M., Buriolla, S., Bertoli, E., Vitale, M. G., Rossi, E., Schinzari, G., Minisini, A. M., & Puglisi, F. (2020) · Cancers · doi:10.3390/cancers12071941 · Cited by 6
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches
Tarhini, A. A., Castellano, E., & Eljilany, I. (2024) · The Cancer Journal · doi:10.1097/ppo.0000000000000706 · Cited by 6
Figueiredo, A. B., Silva, M. J. B. E., Evangelista, G. F. D. B., Galdino, N. A. D. L., Kuil, L. D. M., Santos, I. P., Morais, K. L. P., Cavalcanti, C. M., Moredo, L. F., Neto, J. P. D., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32624 · Cited by 6
Hussein, N. I., Molina, A. H., Sunga, G. M., Amit, M., Lei, Y. L., Zhao, X., Hartgerink, J. D., Sikora, A. G., & Young, S. W. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106986 · Cited by 6
Yacoub, I., Rayn, K. N., Choi, J. I., Bakst, R. L., Chhabra, A. M., Qian, J. Y., Johnstone, P. A. S., & Simone, C. B. (2024) · Cancers · doi:10.3390/cancers16233920 · Cited by 6
Smithy, J. W., Peng, X., Ehrich, F. D., Moy, A. P., Yosofvand, M., Maher, C. A., Aleynick, N., Vanguri, R. S., Zhuang, M., Lee, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115554 · Cited by 7
Self-citationBraden, J., Potter, A. J., Rawson, R. V., Adegoke, N. A., Lo, S., Conway, J. W., Menzies, A. M., Carlino, M. S., Au‐Yeung, G., Saw, R. P. M., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100776 · Cited by 6
Neoadjuvant Therapy for Melanoma
Lowe, M., & Kudchadkar, R. R. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.03.001 · Cited by 6
Yokouchi, H., Nishihara, H., Harada, T., Amano, T., Ohkuri, T., Yamazaki, S., Kikuchi, H., Oizumi, S., Uramoto, H., Tanaka, F., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1971430 · Cited by 6
Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
Ferraresi, V., & Vari, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1971015 · Cited by 6
Neoadjuvant therapy for melanoma: new and evolving concepts.
Erstad, D. J., Witt, R. G., & Wargo, J. A. (2022) · PubMed · Cited by 6
Self-citationNeoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
van Akkooi, A. C. J., Zijlker, L. P., & Wouters, M. W. J. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00525-x · Cited by 6
Rhodin, K. E., Gaughan, E. M., Raman, V., Salama, A. K. S., Hanks, B. A., Shah, R., Tyler, D. S., Slingluff, C. L., & Beasley, G. M. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005459 · Cited by 7
A Review of Immune Checkpoint Blockade for the General Surgeon
Baldwin, X. L., Spanheimer, P. M., & Downs‐Canner, S. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.08.040 · Cited by 6
Research landscape and trends of melanoma immunotherapy: A bibliometric analysis
Liu, Y., Yu, L., Liang, Y., Cheng, X., Jiang, S., Yu, H., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024179 · Cited by 6
Updates in management strategies of locally advanced sinonasal malignancy
Yaniv, D., & Su, S. Y. (2023) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000866 · Cited by 6
Hsu, M., Martin, T. C., Vyas, N. S., Desman, G. T., Mendelson, K., Horst, B. A. J., Parsons, R. E., & Celebi, J. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13091 · Cited by 6
Moine, M. L., Azouz, A., Sanchez, G. S., Dejolier, S., Nguyen, M., Thomas, S., Shala, V., Dreidi, H., Denanglaire, S., Libert, F., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112876 · Cited by 8
Clinical updates in neoadjuvant immunotherapy for melanoma before surgery
Saad, M., Castellano, E., & Tarhini, A. A. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2248392 · Cited by 6
Immunotherapy of Human Melanoma: Past, Present, Future
Mortezaee, K., & Majidpoor, J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673283943240227104122 · Cited by 6
Updates in the evidence‐based management of cutaneous melanoma
Goepfert, R. P., Myers, J. N., & Gershenwald, J. E. (2020) · Head & Neck · doi:10.1002/hed.26398 · Cited by 6
Self-citationAdjuvant and Neoadjuvant Therapies in Cutaneous Melanoma
Ponto, J., & Bell, R. B. (2022) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2021.11.010 · Cited by 7
Lawless, A. K., Coker, D. J., Lo, S., Ahmed, T., Scolyer, R. A., Ch’ng, S., Nieweg, O. E., Shannon, K. F., Spillane, A. J., Stretch, J. R., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11997-0 · Cited by 6
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaPreprint
Nolan, G. P., Phillips, D. J., Matusiak, M., Rivero‐Gutiérrez, B., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-122285/v1 · Cited by 6
Coelho, K. M. D. P. A., de Macêdo, M. P., Lellis, R. F., Pinheiro, N. D. F., Rocha, R. F., & Xavier‐Júnior, J. C. C. (2025) · Surgical and Experimental Pathology · doi:10.1186/s42047-025-00178-4 · Cited by 6
Current Therapies and Potential Strategies for Uveal Melanoma
Scoles, S., Ganesh, S., & Yamada, K. H. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020014 · Cited by 5
Exosomal Non-coding RNAs: A New Approach to Melanoma Diagnosis and Therapeutic Strategy
Liu, J., Hu, X., Xin, W., & Wang, X. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673267553231017053329 · Cited by 5
Gide, T. N., Mao, Y., Scolyer, R. A., Long, G. V., & Wilmott, J. S. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1109 · Cited by 7
Karine, B., Mortier, L., Dereure, O., Dalac, S., Montaudié, H., Legoupil, D., Dutriaux, C., Quatrebarbes, J. D., Maubec, E., Leccia, M. ‐., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae470 · Cited by 5
Liu, S., Li, X., Wu, C., Yao, L., Dong, H., Zhang, H., Wang, Y., Wang, M., & Xu, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002528 · Cited by 5
Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025
Fukushima, S., Ito, T., Asai, J., Igaki, H., Tanaka, R., Namikawa, K., Hayashi, A., Minagawa, A., Miyagawa, T., Miyashita, A., et al. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17740 · Cited by 6
Fomchenko, E. I., Leelatian, N., Darbinyan, A., Huttner, A. J., & Chiang, V. (2022) · Journal of Neurosurgery Case Lessons · doi:10.3171/case21373 · Cited by 5
Kuczkiewicz‐Siemion, O., Sokół, K., Puton, B., Borkowska, A. M., & Szumera‐Ciećkiewicz, A. (2022) · Cancers · doi:10.3390/cancers14153833 · Cited by 5
Fifty years of progress in surgical oncology: Melanoma
Coit, D. G., & Ariyan, C. E. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27081 · Cited by 5
van Akkooi, A. C. J. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14416-0 · Cited by 5
Abdulrahman, Z., Kortekaas, K. E., Welters, M. J. P., van Poelgeest, M. I. E., & van der Burg, S. H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03755-w · Cited by 5
Chung, D. C., Shakfa, N. E., Vakharia, J., Warner, K., Jacquelot, N., Sayad, A., Han, S., Ghaedi, M., Garcia-Batres, C. R., Sotty, J., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0151 · Cited by 5
Lee, S. L., Al‐Shamkhani, A., & Mirnezami, A. H. (2019) · British journal of surgery · doi:10.1002/bjs.11224 · Cited by 5
Kwak, M., Song, Y., Gimotty, P. A., Farrow, N. E., Tieniber, A. D., Davick, J. G., Tortorello, G. N., Beasley, G. M., Slingluff, C. L., & Karakousis, G. C. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07694-0 · Cited by 5
Paulsen, J. D., Zeck, B., Sun, K., Simões, C., Theise, N. D., & Chiriboga, L. A. (2020) · Journal of Histotechnology · doi:10.1080/01478885.2020.1807228 · Cited by 5
Indini, A., Lombardo, M., Sidoni, A., Gianatti, A., Mandalà, M., & Massi, D. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000375 · Cited by 5
Krijgsman, O., Kemper, K., Boshuizen, J., Vredevoogd, D. W., Rozeman, E. A., Molero, S. I., de Bruijn, B., Cornelissen‐Steijger, P., Shahrabi, A., Velasco‐Herrera, M. D. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4218 · Cited by 5
CD4, CD20 and PD-L1 as a marker of recurrence in non-muscle invasive bladder cancerPreprint
Semeniuk-Wojtaś, A., Modzelewska, M., Poddębniak-Strama, K., Kołaczyńska, S., Lubas, A., Górnicka, B., Jakieła, A., & Stec, R. (2023) · Research Square · doi:10.21203/rs.3.rs-2888762/v1 · Cited by 5
Mansour, J., & Schmalbach, C. E. (2025) · Cancers · doi:10.3390/cancers17132152 · Cited by 6
Błoński, P. J., Czarnecka, A. M., Ostaszewski, K., Szumera‐Ciećkiewicz, A., & Rutkowski, P. L. (2024) · Biomedicines · doi:10.3390/biomedicines12030669 · Cited by 4
Progress of Exosomes in Cancer Immunotherapy
Wang, Y., Wang, J., Li, H., Deng, S., & Li, Y. (2025) · Cell Biochemistry and Function · doi:10.1002/cbf.70140 · Cited by 4
Karunamurthy, A. D., Chauvin, J.-M., Morrison, R., Bai, Y., Sun, J., Wang, H., Hartman, D. J., Stein, J., Deitrick, C., Bao, R., et al. (2022) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2022-sitc2022.0605 · Cited by 4
Birinapant Reshapes the Tumor Immunopeptidome and Enhances Antigen Presentation
Zhang, W., Sun, S., Zhu, W., Meng, D., Hu, W., Yang, S., Gao, M., Yao, P., Wang, Y., Wang, Q., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073660 · Cited by 4
Management of Localized Melanoma in the Anti-PD-1 Era
Novis, E., & van Akkooi, A. C. J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01556-z · Cited by 4
Neoadjuvant Therapy in Melanoma
Farooq, M. S., Tidwell, J. C., & Karakousis, G. C. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.11.005 · Cited by 4
Mahumud, R. A., Law, C. K., Ospino, D. A., de Wilt, J. H. W., van Leeuwen, B. L., Allan, C. P., Vazquez, V. D. L., Jones, R. P., Howle, J. R., Peric, B., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17040-2 · Cited by 4
Metadata
- Authors
- Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., Diab, A., Wong, M. K., Royal, R., Gross, N., Weber, R., Lai, S. Y., Ehlers, R., Blando, J., Milton, D. R., Woodman, S., Kageyama, R., Wells, D. K., Hwu, P., Patel, S. P., Lucci, A., Hessel, A., Lee, J. E., Gershenwald, J., Simpson, L., Burton, E. M., Posada, L., Haydu, L., Wang, L., Zhang, S., Lazar, A. J., Hudgens, C. W., Gopalakrishnan, V., Reuben, A., Andrews, M. C., Spencer, C. N., Prieto, V., Sharma, P., Allison, J., Tetzlaff, M. T., & Wargo, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Wargo, Jennifer A.
- ORCID
- Amaria, Rodabe N.
- Reddy, Sangeetha M.
- Tawbi, Hussein A.
- Davies, Michael A.
- Ross, Merrick I.
- Cormier, Janice N.
- Lewis, Carol
- Hwu, Wen-Jen
- Hanna, Ehab
- Diab, Adi
- Wong, Michael K.
- Gross, Neil
- Weber, Randal
- Lai, Stephen Y.
- Blando, Jorge
- Woodman, Scott
- Kageyama, Robin
- Wells, Daniel K.
- Hwu, Patrick
- Patel, Sapna P.
- Lucci, Anthony
- Lee, Jeffrey E.
- Gershenwald, Jeffrey
- Burton, Elizabeth M.
- Haydu, Lauren
- Wang, Linghua
- Zhang, Shaojun
- Lazar, Alexander J.
- Hudgens, Courtney W.
- Gopalakrishnan, Vancheswaran
- Reuben, Alexandre
- Andrews, Miles C.
- Spencer, Christine N.
- Prieto, Victor
- Sharma, Padmanee
- Allison, James
- Tetzlaff, Michael T.
- Wargo, Jennifer A.
- Venue
- Nature Medicine
- Published
- 2018-10-08
- Volume
- 24
- Issue
- 11
- Pages
- 1649-1654
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6481682
- OpenAlex
- W2894584497
- Semantic Scholar
- 251ac2984307dc31d5a4596caa7a07c90195b1e8
- Cited by
- 835
- References
- 31
- Citations by year
- 2026: 49 · 2025: 80 · 2024: 102 · 2023: 116 · 2022: 119 · 2021: 130 · 2020: 142 · 2019: 79 · 2018: 12
- FWCI
- 34.49
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense
- Bristol-Myers Squibb
- Nature
- National Institutes of Health (UL1TR000371)
- University of Texas MD Anderson Cancer Center
- National Cancer Institute (T32CA009666, K08CA160692)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- melanoma, nivolumab, ipilimumab, combination immunotherapy, pathological complete response, T cell infiltration, lymphocyte infiltration, treatment-related adverse events, biomarkers
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Risk Factors, Disease-Free Survival, Neoadjuvant Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
